Floatz logo

BICALUTAMIDE

Metastatic Prostate Carcinoma

Washington University School of MedicineSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

228 Active assets in the Metastatic Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
Pembrolizumab
CuraCell TX AB
Phase 2BB

View all 50 →

Same molecule, other indications

BICALUTAMIDE is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →